Clinical trials: Rosacea, Papulopustular
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Rosacea
Genetic Basis of Rosacea Study (Control)
Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. It it considered to be a syndrome encompassing various combinations of cutaneous signs including…
- Trial name
- NCT02749786
- Testing
- Skin Biopsy
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Rosacea, Papulopustular Rosacea
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
To evaluate the efficacy of once-daily application of 1% and 3% HY01 Topical Gel, as assessed by the change in inflammatory lesion count from baseline over the 12-week treatment period in patients with moderate-to-severe…
- Trial name
- NCT03263273
- Testing
- 1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
- Where
- 23 sites in United States
- Volunteers
- 270 people
- Sponsor
- Hovione Scientia Limited
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea
- Trial name
- NCT02052999
- Testing
- PAC-14028 cream 1%, Vehicle, Rozex gel 0.75%
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Amorepacific Corporation
Papulopustular Rosacea
Deucravacitinib Rosacea
This will be a double-blind, randomized placebo-controlled study in which participants will be randomized 2:1 to receive 6 mg deucravacitinib or placebo once daily for 8 weeks, followed by an open label extension during which all…
- Trial name
- NCT06532136
- Testing
- Deucravacitinib
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Papulopustular Rosacea
A Safety and Efficacy Study to Evaluate Rosacea
To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.
- Trial name
- NCT03883945
- Testing
- AIV001, Vehicle
- Where
- United States
- Sponsor
- AiViva BioPharma, Inc.
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer…
- Trial name
- NCT03079531
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Anne Chang
Moderate to Severe Papulopustular Rosacea
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.
- Trial name
- NCT03050086
- Testing
- BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioPharmX, Inc.
Rosacea, Papulopustular
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.
- Trial name
- NCT03418610
- Testing
- Azelaic Acid foam 15%
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Clinical Research Center of the Carolinas
Rosacea, Papulopustular
Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device
10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device
- Trial name
- NCT05592548
- Testing
- cold atmospheric plasma
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Skin Center Dermatology Group
Rosacea, Papulopustular Rosacea
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
The purpose of this study is to see if the study drug, FMX-103, is safe to give and if it helps people with moderate-to-severe papulopustular rosacea. The investigational product is FMX-103 minocycline foam.
- Trial name
- EMIRA (NCT02601963)
- Testing
- FMX-103 1.5%, FMX-103 3%, Vehicle foam (0%)
- Where
- 20 sites in Germany
- Volunteers
- 233 people
- Sponsor
- Vyne Therapeutics Inc.
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
- Trial name
- NCT01555463
- Testing
- Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
- Where
- 49 sites in United States
- Volunteers
- 961 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.
- Trial name
- NCT01257919
- Testing
- Azelaic Acid Foam, Azelaic Acid Gel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.